z-logo
open-access-imgOpen Access
The magnitude of extended-spectrum beta-lactamase- producing Enterobacteriaceae from clinical samples in Ethiopia: a systematic review and meta-analysis
Author(s) -
Kuma Diriba,
Ephrem Awulachew,
Aschelew Gemede,
Asrat Anja
Publication year - 2021
Publication title -
access microbiology
Language(s) - English
Resource type - Journals
ISSN - 2516-8290
DOI - 10.1099/acmi.0.000195
Subject(s) - enterobacteriaceae , imipenem , cefotaxime , medicine , ceftazidime , amikacin , meta analysis , microbiology and biotechnology , biology , antibiotic resistance , antibiotics , escherichia coli , pseudomonas aeruginosa , bacteria , biochemistry , genetics , gene
Background The rapid spread of resistance among extended-spectrum β-lactamase (ESBL)-producingEnterobacteriaceaeis a serious problem around the world. It results in serious clinical complications in humans and has become a global threat. Therefore, this systematic review and meta-analysis was aimed to estimate the pooled prevalence of ESBL-producingEnterobacteriaceaein different clinical samples in Ethiopia. Methods A systematic search was conducted on PubMed, Web of Science, Embase, Google Scholar and the Cochrane Library. All identified observational studies reporting the prevalence of ESBL-producingEnterobacteriaceaefrom clinical samples in Ethiopia were included. Four authors independently extracted data and analysed using R software version 3.6.1 and STATA statistical software version 13. A random-effects model was computed to estimate the pooled prevalence of ESBL-producingEnterobacteriaceaein Ethiopia. Results Of 142 articles reviewed, 14 studies that fulfilled the inclusion criteria were included in the meta-analysis. The pooled prevalence of ESBL-producingEnterobacteriaceaein the different clinical specimens in Ethiopia was 49 % (95 % CI: 39, 60).Klebsiella pneumoniaewas the leading ESBL-producingEnterobacteriaceaefollowed byEscherichia coliandAcinetobacter baumanniiwith a prevalence of 74, 67 and 60 %, respectively. ESBL-producing isolates showed a high rate of resistance to cefotaxime, ceftriaxone, ceftazidime, Amoxicillin clavulanic acid (AMC), ampicillin and aztreonam. The better options for the treatment of ESBL-producingEnterobacteriaceaeare amikacin and Imipenem. Conclusion The magnitude of ESBL-producingEnterobacteriaceaein different clinical samples in Ethiopia is alarmingly high and represents a threat to human health. Hence, a coordinated effort needs to be implemented for the prevention and control of theseEnterobacteriaceae .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom